Meeting of the Oncologic Drugs Advisory Committee Meeting Announcement

https://www.fda.gov/advisory-committees/advisory-committee-calendar/updated-public-participation-information-july-14-2020-meeting-oncologic-drugs-advisory-committee?utm_campaign=FDA%20Stakeholder%20Update%20-%20July%202%2C%202020&utm_medium=email&utm_source=Eloqua#event-information

Meeting of the Oncologic Drugs Advisory Committee Meeting Announcement

The committee will discuss biologic license application (BLA) 761158, for belantamab mafodotin, submitted by GlaxoSmithKline Intellectual Property Development Ltd. England. The proposed indication (use) for this product is for the treatment of adults with relapsed or refractory multiple myeloma who have received at least four prior therapies including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent.

Date: July 14, 2020     Time: 9:00 AM - 1:30 PM ET

Registration is not required.